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Abstract
Background: Trachoma is the leading preventable cause of global blindness. A balanced Th1/Th2/Th3 immune response is
critical for resolving Chlamydia trachomatis infection, the primary cause of trachoma. Despite control programs that include
mass antibiotic treatment, reinfection and recurrence of trachoma are common after treatment cessation. Furthermore, a
subset of infected individuals develop inflammation and are at greater risk for developing the severe sequela of trachoma
known as trachomatous trichiasis (TT). While there are a number of environmental and behavioral risk factors for trachoma,
genetic factors that influence inflammation and TT risk remain ill defined.
Methodology/Findings: We identified single nucleotide polymorphisms (SNP) in 36 candidate inflammatory genes and
interactions among these SNPs that likely play a role in the overall risk for TT. We conducted a case control study of 538
individuals of Tharu ethnicity residing in an endemic region of Nepal. Trachoma was graded according to World Health
Organization guidelines. A linear array was used to genotype 51 biallelic SNPs in the 36 genes. Analyses were performed
using logic regression modeling, which controls for multiple comparisons. We present, to our knowledge, the first
significant association of TNFA (-308GA), LTA (252A), VCAM1 (-1594TC), and IL9 (T113M) polymorphisms, synergistic SNPs
and risk of TT. TT risk decreased 5 times [odds ratio=0.2 (95% confidence interval 0.11.–0.33), p=0.001] with the
combination of TNFA (-308A), LTA (252A), VCAM1 (-1594C), SCYA 11 (23T) minor allele, and the combination of TNFA (-
308A), IL9 (113M), IL1B (59UTR-T), and VCAM1 (-1594C). However, TT risk increased 13.5 times [odds ratio=13.5 (95%
confidence interval 3.3–22), p=0.001] with the combination of TNFA (-308G), VDR (intron G), IL4R (50V), and ICAM1 (56M)
minor allele.
Conclusions: Evaluating genetic risk factors for trachoma will advance our understanding of disease pathogenesis, and
should be considered in the context of designing global control programs.
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Introduction
Trachoma is a chronic ocular disease caused by Chlamydia
trachomatis, although other chlamydial species have recently been
implicated in trachomatous inflammation and disease [1].
Trachoma remains the primary preventable cause of visual
impairment and blindness in the world [2]. Repeated and/or
persistent ocular infections and inflammation can result in
subsequent conjunctival scarring and fibrosis, leading to entropion
(distorted eyelid) and trichiasis (TT;$one in-turned eyelash
touching the globe of the eye) [3]. TT represents an important
threat to vision because of the development of corneal abrasions
and subsequent opacity [3,4].
The World Health Organization (WHO) developed the SAFE
strategy [Surgery, Antibiotic treatment, Facial cleanliness, Envi-
ronmental improvement] to eliminate blinding trachoma by the
year 202 [5]. However, mass or targeted antibiotics has resulted in
the recurrence of trachoma and infection after treatment cessation
in multiple studies [6–9]. Consequently, there has been a
continued focus on understanding host immune responses for
each grade of trachomatous disease along with chlamydial
infection to provide the knowledge to enhance control programs
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3600and vaccine development, and assess vaccine efficacy once one
becomes available.
Humoral and cell mediated immune responses are considered
essential in both the clearance of chlamydial infection and in the
immunopathogenesis of trachomatous disease, although the
pathogenic mechanisms remain unclear. Cell mediated immunity
is primarily controlled by cytokines at the local mucosal
microenvironment [10]. The contribution and presence of a
particular cytokine may vary according to the stage of infection or
grade of trachoma. Some studies have evaluated cytokine mRNA
gene expression in trachoma and found that transforming growth
factor beta (TGF-b) and the pro-inflammatory cytokines, inter-
leukin-1 beta (IL-1b) and tumor necrosis factor alpha (TNF-a),
were significantly elevated in trachomatous follicular inflammation
(TF) and trachomatous scarring (TS) [11–13]. We recently
expanded on the characterization of cytokines and also identified
chemokines involved in the immunopathology of different grades
of trachoma using a more robust approach that involved
conjunctival mucosal protein quantitation. Our findings highlight
the importance of Th1 cytokines in protection against TS as
evidenced by decreased protein levels for IL-12p40 compared with
controls [14]. Additionally, we identified involvement of the Th2
cytokines IL-4 and IL-13 in eliciting protective immunity, and IL-
10 and IL-15 as possible Th3/Tr1 cytokines and risk factors for
TS. IL-1b was also a strong risk factor for scarring while its
antagonist, IL-1Ra, was protective. C. trachomatis infection was
significantly associated with elevated proinflammatory TNF-a and
IL-6 cytokines, the Th3/Tr1 IL-10 and IL-15 cytokines, and the
Th1-associated chemokines MIP-1b and RANTES in the
presence of trachomatous disease, suggesting an added microbial
influence on trachoma pathogenesis.
To further characterize the host immune response, it will be
necessary to evaluate host genetic susceptibility to the development
of trichiasis. This is particularly important because some
individuals in trachoma endemic areas develop severe inflamma-
tion with each infection while others in the same community do
not, despite similar environmental and ethnic backgrounds [3].
Furthermore, the former are significantly more likely to develop
TS and TT [3,15].
There have been some studies evaluating the association
between single nucleotide polymorphisms (SNPs) among inflam-
matory genes and trachomatous disease [16–20]. In Gambia,
Th1/Th2/Th3 gene SNPs, including IFNG (+3234 C), IL-10
(+5009 G, 21082 G only in the Mandinka ethnic group, and
23575A), and TNFA (2308 A), were found to be associated with a
higher odds of having TS [16], while TNFA (2308 GA) and
lymphotoxin alpha [LTA, +252 GG, and inhibitor of kappa light
chain gene enhancer in B-cells-like (IKBL, 263 TT) SNPs were
significantly associated with TS or TT [16,17,19,20]. SNPs in
LTA (+77 G.T), TNFA (2238 G.A, 2376 G.A), inhibitor of
kappa light chain gene enhancer in B-cells, alpha (IKBA, 2881
A.G, 2826 C.T, 2297 C.T), IFNG (21616 C.T, +2200
T.C, +5612 C.T), IL-4 (2590 T.C) and IL10 (21082 T.Co r
A.G, 2819 C.T, 2592 A.C or G.T) were not associated with
TS or TT [16–20]. For the IL10 (21082) polymorphism, the
literature is contradictory (T.C [19] or A.G [17]). More
recently, researchers found that heterozygosity for the Q279R
polymorphism in matrix metalloproteinase 9 (MMP-9), which
plays a role in tissue remodeling, was associated with lower risk for
scarring trachoma compared to homozygosity for the ‘‘A’’ allele
(i.e.Q279) [21]. These findings suggest a role for SNPs in the
pathogenesis of trachoma. However, all of these studies were
conducted in Gambia, and only two of these used TT as the
outcome. Similar studies need to be replicated among trachoma
endemic populations in other countries. Additionally, there are a
plethora of inflammatory genes and SNPs that remain to be
characterized in association with trachoma.
The purpose of the present study was to expand on previous
SNP research and determine whether subjects with TT were more
likely to have particular SNPs compared to subjects without any
evidence for trachoma. We screened 51 SNPs derived from 36
biologically plausible candidate genes encoding proteins in
inflammatory pathways to identify genetic markers that may assist
in elucidating the pathogenesis of trachoma in a Nepali
population. To our knowledge, this is the first study to examine
such a large array of inflammatory SNP markers in association
with trachomatous disease.
Materials and Methods
Study Population and Trachoma Grading
The study and written informed consent for the study were
approved by the Institutional Review Boards of Children’s
Hospital and Research Center at Oakland, CA, and the Nepal
Netra Jhoti Sang, Kathmandu, Nepal, according to the Conven-
tion of Helsinki. A survey was conducted in a trachoma endemic
region of Kapilvastu District, Lumbini Zone, Nepal. All study
participants were of the Tharu ethnic group. Trachoma grading
was performed using the modified grading scale according to
WHO guidelines as described previously [22,23]. Briefly, subjects
with ,5 follicles on the lower 2/3 of the upper tarsus were defined
as having no trachoma. Trachomatous inflammation, follicular
(TF) was defined as five or more follicles in the upper tarsus,
trachomatous inflammation, intense (TI) as intense inflammatory
thickening of upper tarsal conjunctiva with indistinct deep tarsal
vessels, trachomatous scarring (TS) as the presence of scarring in
the upper tarsus, and trachomatous trichiasis (TT) as at least one
in-turned eyelash rubbing the eyeball or history of epilation
(removal of in-turned eyelashes). After obtaining informed
consent, research staff enumerated and clinically examined all
household members in two villages in the district.
Whole blood samples collected in ethylenediaminetetraacetic
acid (EDTA) containing tubes and conjunctival swabs were
obtained from all villagers as previously described [1,23]. Briefly,
the upper tarsal conjunctivae of both eyes were swabbed with a
Dacron swab (American Scientific Products, McGraw Park, IL).
Swabs were placed in collection media (M4-RT; Micro-Test,
Lilburn, GA). A new set of gloves was used for each subject to
prevent cross-contamination of C. trachomatis. All the samples were
dated and coded with a unique ID number to maintain
confidentiality and to process samples in a masked fashion. The
samples were immediately placed in liquid nitrogen transport
tanks for transfer to Children’s Hospital Oakland Research
Institute where the samples were then stored at 280uC until
processed.
Detection of Chlamydia trachomatis
The Amplicor-PCR assay (Roche Diagnostics, Branchburg, NJ)
was used to detect C. trachomatis for each conjunctival sample
according to the manufacturer’s instructions and as we described
previously [1,14,23]. Of note is that gloves were used in between
subjects to prevent cross-contamination of the collected samples.
Optical density (OD) was measured at 450 nm using an
automated microwell plate reader. Samples were defined as
positive with an OD450 nm of $0.8, negative with an OD450 nm of
#0.2, and equivocal with an OD450 nm between 0.2 to 0.8. All
equivocal samples were reevaluated by an in-house validation
PCR test to further assess the presence or absence of chlamydiae
Trichiasis Associated SNPs
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conjunctival swabs was amplified using primers that flank the
ompA gene. PCR products of the same molecular weight size as the
PCR positive control were considered positive as long as the
negative control was negative.
Extraction of Genomic DNA
Genomic DNA was extracted from whole blood using
Genovision GenoM
TM (GenoVision Inc., West Chester, PA),
according to manufacturer’s instructions. The principle of DNA
isolation and purification by GenoVision technology is that DNA
binds to the glass surface of magnetic beads in the presence of a
chaotropic solution. Cell lysis is followed by binding of DNA to
magnetic beads, washing and elution of the DNA. The
concentration of the DNA was determined using a spectropho-
tometer at OD260 nm.
Linear array for SNP detection
We used an immobilized probe linear array assay developed by
Roche Molecular Systems (Alameda, CA) to genotype 51 biallelic
SNPs in 36 genes associated with inflammation as previously
described by Barcellos et al.[24], although in the referenced study,
only 34 genes were used. The selection of SNPs was based on
publicly available databases that included Caucasian and Chinese
data. Briefly, 25 ng of genomic DNA from each sample was
amplified by multiplex PCR using biotinylated primers for all 51-
gene polymorphisms. Two probes were designed for each biallelic
site to detect and distinguish between variant sequences. The PCR
product was denaturated with 10 ml Amplicor base streptavidin-
HRP and a colorless soluble substrate, which is converted into a
blue precipitate. Bands on the developed arrays were aligned to a
guide to identify the respective allele, and the arrays were scanned
into a computer (Figure 1). SNP interpretations were made
independently by two individuals masked as to all subject data.
Data Analysis
Allele and genotype frequencies were compared for cases (TT)
vs. controls (no evidence for TF, TI, TS or TT) by chi-square test.
Hardy-Weinberg equilibrium (HWE) was tested for each SNP. We
performed simple and multiple logistic regression analysis; age,
sex, having TF, TI, TS, TT and C. trachomatis infection status were
covariates included in multiple logistic regression. Finally, we
performed logic regression to analyze interactions among multiple
SNPs.
Logic regression was used to identify gene-gene interactions
[25]. Correction for multiple comparisons is not considered
necessary in logic regression since the multi-step model selection is
very precise and thereby accounts for multiple comparisons [25].
Instead of cross-product terms that are used in logistic regression,
logic builds Boolean expressions in the form of ‘‘and/or’’ trees (L)
to identify gene interactions. A simulated annealing algorithm is
used to predict logic trees. The annealing algorithm works by
starting from a particular state and then selecting a move to a new
state. The score of the new state is compared with the score of the
old state. If the score of the new state is better than the score of the
old state, the move is accepted. We chose to use the simulated
annealing algorithm because it is a robust technique for nonlinear
models even though it is computationally very demanding.
We used logic regression within the context of logistic
regression. In this study, the outcome was binary [subjects having
TT (cases) or no evidence for any trachoma grade (controls)].
Deviance was used as the scoring function. We used the 10-fold
cross-validation test, comparing the best model to models of
different sizes. In addition, we used randomization tests to
determine optimal model size. In order to carry out a null-model
test for signal in the data, an initial ‘‘best scoring’’ model, allowing
up to two trees and eight leaves (the default maximum tree size
provided by the function ‘‘logreg’’) was obtained. The score of this
‘‘best model’’ was then compared to the distribution of scores
obtained by repeatedly permuting the outcome and refitting the
data. The proportion of scores from the permuted data that are
better than the best score of the original data is reported as an
exact p-value. We used the more conservative p-value of less than
0.001 as a cut-off for statistical significance in the logic analysis.
Results
Clinical and Demographic Characteristics of Study
Population
The study population comprised individuals from a trachoma
endemic region of Southwestern Nepal. Characteristics of the
study population are summarized in Table 1. Having TT was
significantly associated with older age [O.R.=1.07 (1.05–1.09), p-
value=0.001] and being female [O.R.=3.1 (2–4.8), p-val-
ue=0.001], which is consistent with the literature [3,26,27].
The prevalence of C. trachomatis infection was 11.3% (22/194) for
controls, 48 (27.6%) for those with TF and/or intense trachoma-
tous inflammation (TI), and 16.5% (21/127) for TT cases. Other
studies have also found high infection rates among TT cases
[23,28,29] and high rates among controls [6,30–32].
Genomic frequencies of 51 inflammatory SNPs among TT
cases vs. controls
Because all the cases and controls in the study were of the Tharu
ethnic group, we assumed that population admixture would not be
a confounder in the analyses. Also, because subjects under age 20
years can have TS and TT [33–35], we felt it was reasonable to
include them in our study.
An example of the linear array results are shown in Figure 1; all
samples yielded appropriate readable bands in the array,
suggesting a lack of inhibitors in the PCR and downstream
hybridization. Single allele frequencies by TT status were
compared with controls for the 51 candidate SNPs, and are
summarized in Table 2. We defined major allele as the first allele
that appeared in the inflammatory panel, and minor allele as the
second allele that appeared in the panel. Genotype frequencies
differed significantly by TT compared with controls for TNFA
(2308 G.A), LTA (252 G.A), IL1A (2889 C.T), IL1B (F105F),
IL6 (2174 C.G), VCAM1 (21594 T.C), IL4 (2589 C.T),
IL4R (Q576R, and I50V), IL9 (T113M), CCR3 (P39L), ADRB2
(Q27E, and T164I), CTLA4 (2318 C.T), NOS2A (D346D), and
NOS3 (E298D) polymorphisms (Table 3). All observed genotype
frequencies between TT cases and controls in our study were in
HWE.
After multivariate logistic analysis controlling for age, sex, TF,
TI, and C. trachomatis infection status, only certain SNPs remained
significantly associated with TT compared to the controls
(Table 4). The pro-inflammatory TNFA (2308 G.A), and LTA
(+252 G.A), the adhesion molecule VCAM1 (21594 T.C), and
the Th2 cytokine IL-9 (T113M) gene SNPs were significantly
associated with TT cases compared with controls. For TNFA
(2308 G.A), heterozygosity was associated with significantly
decreased odds of TT compared with homozygosity for the major
genotype [O.R.=0.45 (0.25–0.81), p=0.008]. Similarly, the odds
of TT were less in homozygous minor allele individuals
[O.R.=0.25 (0.09–0.63), p=0.004] compared with individuals
with homozygous major allele genotype for the LTA (252 G.A)
polymorphism.
Trichiasis Associated SNPs
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was associated only with VCAM1 (21594 T.C). The odds ratio
for heterozygous individuals was significantly less [O.R.=0.47
(0.25–0.86), p=0.015] than for individuals with the homozygous
major allele genotype (Table 4).
Among the cytokines associated with T helper lymphocyte
polarity, we found that the heterozygous IL9 (T113M) genotype
was a likely protective factor against TT compared with
individuals homozygous for the major genotype (Table 4,
O.R.=0.25 (0.10–0.64), p=0.004).
Although we controlled for age and sex in the analyses as described
above, we also stratified subjects by age and sex, controlling for
infection, and reanalyzed the data. We found similarly statistically
significant results as above (Tables S1, S2, S3, S4).
Figure 1. Representative linear array results for Strip 1 for samples from six Tharu individuals from a trachoma endemic area of
Nepal. Bands represent wild type and SNP probes (see methods). Strip 1 contains 25 SNPs. Strip 2 contains 26 SNPs (not shown). To the left and right
of the probes are the names of the alleles; horizontal blur lines represent amplified alleles.
doi:10.1371/journal.pone.0003600.g001
Table 1. Characteristics of Study Population.
Characteristics Control (n=232) TF/TI (n=204) TT* (n=135)
Age in years (mean+/2sd) 30.8 (16.8) 35.2 (18.1) 51 (14.2)
{
Sex (%)
{ Female (%) 95 (41%) 133 (65.8%) 100 (74.1%)
Male (%) 137 (59%) 69 (34.2%) 35 (25.9%)
C. trachomatis-positive
{ (%) 22 (11.3%) 48 (27.6%)
{ 21 (16.5%)
*TT includes cases with or without TF and/or TI.
{Statistically significant difference at a level=0.001 by two sampled t-test (age) or Pearson chi-square test (sex, C. trachomatis-positive).
{Amplicor PCR test was used to determine C. trachomatis infection status and was available for 194 controls, 174 TF/TI and 127 TT cases.
doi:10.1371/journal.pone.0003600.t001
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Major allele frequency
Gene category Gene (symbol) SNP
Nuc
change rs no*
TT
(n=135)
Controls
(n=232) P
Proinflammatory cytokine genes Tumor necrosis factor- alpha (TNFA) 2308 G)A 1800629 0.83 0.68 0.001
Tumor necrosis factor- alpha (TNFA) 2238 G)A 361525 0.97 0.98 0.402
Lymphotoxin alpha (LTA) 252 G)A 909253 0.63 0.49 0.001
Interleukin 1 alpha (IL1A) 2889 C)T 1800587 0.24 0.32 0.023
Interleukin 1 beta (IL1B)
{ 21418 C)T 16944 0.50 0.42 0.031
Interleukin 1 beta (IL1B) F105F C)T 1143634 0.92 0.84 0.001
Interleukin 6 (IL6) 2572 G)C 1800796 0.46 0.45 0.818
Interleukin 6 (IL6) 2174 C)G 1800795 0.95 0.99 0.002
Adhesion molecule genes Intracelluler adhesion molecule-1 (ICAM1) K56M A)T 5491 0.89 0.90 0.701
Intracellular adhesion molecule-1 (ICAM1)
{ G214R A)G 1799969 0.98 0.99 0.714
Vascular cell adhesion molecule-1 (VCAM1) 21594 T) C 1041163 0.79 0.73 0.092
Selectin E (SELE) S149R A)C 5361 0.92 0.95 0.510
Selectin P (SELP) S330N A)G 6131 0.73 0.80 0.035
Selectin P (SELP) V640L G)T 6133 0.98 0.91 0.012
Th1/Th2/Th3 cytokines and related
genes
Interleukin-4 (IL4) 2589 C)T 2243250 0.47 0.38 0.010
Interleukin 4 receptor (IL4R) Q576R A)G 1801275 0.72 0.64 0.034
Interleukin 4 receptor (IL4R) S478P T)C 1805015 0.89 0.87 0.723
Interleukin 4 receptor (IL4R) I50V A)G 1805010 0.49 0.56 0.078
Interleukin 5 receptor alpha (IL5RA) 280 G)A 2290608 0.76 0.69 0.034
Interleukin 9 (IL9) T113M C)T 2069885 0.96 0.84 0.001
Interleukin 10 (IL10) 2571 C)A 1800872 0.55 0.57 0.817
Interleukin 13 (IL13) Intron3 C)T 1295686 0.64 0.60 0.272
Chemokines and related genes Small inducible cytokine subfamily A (a.k.a eotaxin,
SCYA11)
A23T C)T 3744508 0.84 0.86 0.666
Small inducible cytokine subfamily A (a.k.a eotaxin,
SCYA11)
21328 G)A 4795895 0.93 0.92 0.773
Chemokine (C-C motif) receptor 2 (CCR2) V62I A)G 1799864 0.68 0.69 0.741
Chemokine (C-C motif) receptor 3 (CCR3)
{ P39L C)T 5742906 0.99 0.94 0.001
Chemokine (C-C motif) receptor 5 (CCR5)
{ 32 bp del 333 0.98 1 0.650
Chemokine (C-C motif) receptor 5 (CCR5) 22454 A)G 1799987 0.46 0.45 0.746
Miscellaneous Adrenergic receptor beta 2 (ADRB2) R16G A)G 1042713 0.47 0.39 0.075
Adrenergic receptor beta 2 (ADRB2) Q27E C)G 1042714 0.85 0.77 0.007
Adrenergic receptor beta 2 (ADRB2)
{ T164I C)T 1800888 0.99 0.90 0.001
Fc fragment of IgE, receptor for beta subunit (FCER1B) E237G A)G 569108 0.79 0.75 0.174
CD14 antigen (CD 14) 2260 T)C 2569190 0.43 0.43 1
Transforming growth factor-1 beta (TGF1B) 2509 C)T 1800469 0.58 0.55 0.488
Uteroglobin (UGB) 38 G/A G)A 3741240 0.55 0.58 0.354
T-cell transcription factor 7 (TCF7) P19T C)A 5742913 0.99 1 0.559
T-cell transcription factor 7 (TCF7)
{ UAS UAS 0.76 0.69 0.034
Complement component 3 (C3) R102G C)G 2230199 0.93 0.96 0.140
Complement component 5 (C5) I802V A)G 17611 0.60 0.63 0.529
Colony stimulating factor (CSF2) I117T T)C 25882 0.52 0.55 0.358
Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) 2318 C)T 5742909 0.85 0.78 0.012
Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) T17A A)G 231775 0.60 0.55 0.143
Leukotriene C4 synthase (LTC4S) 2444 A)C 730012 0.90 0.89 0.803
Nitric oxide synthase-inducible (NOS2A) D346D C)T 1137933 0.87 0.79 0.005
Nitric oxide synthase 3-endothelial cell (NOS3) 2948 A)G 1800779 0.92 0.89 0.303
Nitric oxide synthase 3-endothelial cell (NOS3) E298D G)T 1799983 0.84 0.91 0.006
Trichiasis Associated SNPs
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We further investigated the potential impact of interacting
SNPs. Figure 2 shows the logic trees (L) of interacting SNPs that
are associated with TT. The logic modeling resulted in Logit P
(TT=1| risk inflammatory SNPs)=0.3–1.6*L1+2.6*L2. Accord-
ing to logic modeling, TT risk decreased 5 times (e
21.6=0.2) by
the tree (L1) specifying SNP combinations, namely, individuals
with a combination of (1) TNFA(2308 A) minor allele and LTA
(252 A) minor allele and either VCAM1 (21594C) minor allele or
SCYA 11 (23T) minor allele, or (2) TNFA (2308 A) minor allele
and IL-9 (113M) minor allele and IL1B (59UTR T) minor allele
and VCAM1 (21594 C) minor allele [odds ratio=0.2 (95%
confidence interval 0.11–0.33), p=0.001, Figure 2A]. In the
second tree (L2), TT risk increased 13.5 times [odds ratio=13.5
(95% confidence interval 3.3–22), p=0.001] for individuals
demonstrating a combination of TNFA (2308 G) major allele
and VDR (intron G) minor allele, and either IL4R (50V) minor
allele or ICAM1 (56M) minor allele (Figure 2B).
Discussion
The pathogenesis of trachoma, as in many diseases, is related to
the complex interplay of the environment, pathogen, epigenetic
factors and the host immune response that is intimately related to
host genetic susceptibility to disease. Susceptibility to cerebral
malaria [36], tuberculosis [37], HIV [38], rheumatoid arthritis
[39], multiple sclerosis [40], and Alzheimer disease [41] are
among the diseases found to be associated with SNPs in
inflammatory genes. To date, there are minimal studies linking
polymorphisms in inflammatory genes with the severe end-stage
disease of trachoma, TT.
In this study, we focused on TT as a more accurate clinical sign of
disease outcome than active disease (TF and/or TI) and, therefore,
less susceptible to misclassification and more suitable for genetic
studies of susceptibility. For TF and TI, it is not clear which
individuals with inflammation will go on to develop sequela or clear
the inflammation without progression to disease. Thus, we
considered it best not to classify these individuals as cases or
controls. TF and TI were controlled for in multivariate logistic
regression analysis for these reasons. We also controlled for C.
trachomatis infection because other infectious diseases such as malaria,
tuberculosis and HIV-1 have been shown to be independently
associated with SNPs [36–38], although the association of specific
SNPs with chlamydiae has not been evaluated.
We found an association between TT and polymorphisms in two
genes that are members of the TNF superfamily: TNFA (2308 G.)
and LTA (intron G.A).Bothgenes are located on chromosome6,as
is the major histocompatibility complex (MHC), and are highly
similar structurally and functionally [42]. The cytokines encoded
by these two genes bind the same receptor, which is upregulated
by IFN-c [43]. TNF-a is a major proinflammatory cytokine
secreted by an array of leucocytes in chlamydial infected tissues
[44]. It was first shown in vitro that human recombinant TNF-a
inhibited the growth of C. trachomatis [45]. Following this finding,
the cytotoxic effect of TNF-a on C. trachomatis infected cells was
shown in a murine model of chlamydial genital tract infections
[46]. TNF-a mRNA transcripts and protein levels have been
reported to be significantly higher in subjects who were infected
with chlamydiae than those who were not infected [11,13,14].
Conjunctival TNF-a mRNA levels have also been found to be
positively correlated with duration of infection [13].
The TNFA (2308) polymorphism, located in the promoter
region, has been extensively studied for genetic association with a
variety of diseases. We found 2308 GA (heterozygous) and AA
genotypes to be associated with a decreased odds of TT whereas a
previous study found an association with susceptibility to TT [20].
This might be due to geographic and population differences.
However, it is not clear if there was any adjustment for infection or
active disease status, as in our study. In addition, the p-value cut-
off for statistical significance was 0.048, which is not conservative
for a population based genetic association study. In the same
study, they also found that the TNFA (2308) GA genotype was
correlated with increased TNF-a protein production [20].
However, this finding depended on only three subjects with the
AA genotype. Their p-value by ANOVA was only 0.043, and by
Kruskall-Wallis was 0.075.
Elevated TNF-a levels have been considered protective for C.
trachomatis infection and essential for resolution of active disease
but, it has also been associated with chronic disease [11,13]. More
importantly, the effect of TNFA (2308 G) carried an increased risk
of TT if an individual also carried the VDR (intron G), IL-4R
(50V), and ICAM-1 (56M) minor allele. However, further
quantitative protein studies will be required to characterize the
role of this protein and SNP in TT.
The LTA gene, also known as TNFB, is primarily expressed in
lymphocytes and has been associated with regulating CD8+ T
lymphocytes. Several animal models of genital chlamydial
infection have shown that CD8+ T cells are protective against
chlamydial infection and are necessary for infection clearance
[47,48]. In TT cases, elevated CD8+ T lymphocytes have been
identified in conjunctival samples [49,50]. We found that the LTA
(252 A) variant was significantly associated with a decreased odds
of TT. Interestingly, Natividad et.al. [20] found an association
between LTA (252 G) and TT. We found that the A allele
decreased the odds of TT, given that GG was our reference while
AA homozygosity was their reference.
Major allele frequency
Gene category Gene (symbol) SNP
Nuc
change rs no*
TT
(n=135)
Controls
(n=232) P
Stromal derived factor 1 (SDF1) 39UTR 39UTR 1801157 0.82 0.75 0.016
Vitamin D receptor (VDR) M1T C)T 2228570 0.33 0.38 0.201
Vitamin D receptor (VDR) Intron8 A)G 1544410 0.71 0.75 0.261
*The first allele that appeared in the linear array inflammatory panel was referred to as the major allele; the second allele in the panel was referred to as the minor.
{www.ncbi.nlm.nih.gov/SNP.
{Total number of controls was 230 for ADRB2 (T164I), ICAM1 (G241R), CCR3 (P39L), CCR5 (WTDEL32), TCF7 (P19T); 231 for IL1B (21418); total number of TT cases was
134 for TCF7 (UAS).
doi:10.1371/journal.pone.0003600.t002
Table 2. Cont.
Trichiasis Associated SNPs
PLoS ONE | www.plosone.org 6 October 2008 | Volume 3 | Issue 10 | e3600Table 3. Genotype Distribution by TT Status Based on Univariate Analysis.
Gene category Gene (SNP) Genotype TT (n=135) Controls (n=232) p-value
Proinflammatory cytokine genes TNFA (2308 G.A) GG 91 (67%) 105 (45%) ,0.001
GA 41 (30%) 105 (45%)
AA 3 (3%) 22 (10%)
LTA (252 G.A) GG 51 (38%) 55 (24%) ,0.001
GA 70 (52%) 116 (50%)
AA 14 (10%) 61 (26%)
IL1A (2889 C.T) CC 5 (4%) 11 (5%) 0.002
CT 55 (41%) 127 (55%)
TT 75 (56%) 94 (40%)
IL1B (F105F) CC 116 (86%) 160 (69%) ,0.001
CT 18 (13%) 72 (31%)
TT 1 (1%) 0
IL6 (2174 C.G) CC 123 (91%) 227 (98%) 0.02
CG 11 (8%) 5 (2%)
GG 1 (1%) 0
Adhesion molecule genes VCAM1 (21594 T.C) TT 89 (66%) 118 (51%) 0.001
TC 35 (26%) 104 (45%)
CC 11 (8%) 10 (4%)
Th1/Th2/Th3 cytokines and related genes IL4 (2589 C.T) CC 32 (24%) 25 (11%) 0.004
CT 64 (47%) 125 (54%)
TT 39 (29%) 82 (35%)
IL4R (Q576R) AA 71 (53%) 79 (43%) ,0.001
AG 53 (39%) 141 (51%)
GG 11 (8%) 12 (6%)
IL4R (I50V) AA 37 (28%) 67 (29%) 0.017
AG 60 (44%) 128 (55%)
GG 38 (28%) 37 (16%)
IL9 (T113M) CC 126 (93%) 158 (68%) ,0.001
CT 9 (7%) 73 (32%)
TT 0 1 (0.4%)
Chemokines and related genes CCR3* (P39L) CC 133 (98%) 202 (88%) 0.001
CT 1 (0.1%) 28 (12%)
TT 1 (0.1%) 0
Miscellaneous ADRB2 (Q27E) CC 99 (74%) 134 (58%) 0.011
CG 33 (24%) 90 (39%)
GG 3 (2%) 8 (3%)
ADRB2* (T164I CC 312 (87.1%) 177 (100) 0.001
CT 45 (12.6%) 0
TT 1 (0.3%) 0
CTLA4 (2318 C.T) CC 98 (73%) 134 (58%) 0.016
CT 34 (25%) 92 (40%)
TT 3 (2%) 6 (2%)
NOS2A (D346D) CC 101 (75%) 137 (59%) 0.007
CT 34 (25%) 93 (40%)
TT 0 2 (1%)
NOS3 (E298D) GG 94 (70%) 192 (83%) 0.014
GT 39 (29%) 38 (16%)
TT 2 (1%) 2 (1%)
*Total number of controls were 230 for ADRB2(T164I), CCR3(P39L), total number of TT cases were same as all (n=135).
doi:10.1371/journal.pone.0003600.t003
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Gene category Predicting SNP Genotype O.R. (95% C.I.) for TT P
Proinflammatory cytokine genes TNFA (2308) GG Reference
GA 0.45 (0.25–0.81) 0.008
AA 0.19 (0.04–1.08) 0.062
LTA (252) GG Reference
GA 0.65 (0.35–1.2) 0.173
AA 0.25 (0.09–0.63) 0.004
Adhesion molecule genes VCAM1 (21594) TT Reference
TC 0.47 (0.25–0.86) 0.015
CC 1.06 (0.33–3.4) 0.919
Th1/Th2/Th3 cytokines and related genes IL9 (T113M) CC Reference
CT 0.25 (0.10–0.64) 0.004
TT Dropped due to colinearity NA
*Covariates included in multivariable logistic regression were age, sex, TF/TI, and C. trachomatis infection status for predicting O.R. s with 95% CI.
doi:10.1371/journal.pone.0003600.t004
Figure 2. Logic Tree Models for interacting SNPs associated with TT. TOP, L1 is a combination of (1)TNFA(2308 A) minor allele and LTA (252
A) minor allele and either VCAM-1 (21594 C) minor allele or SCYA 11 (23T) minor allele, or (2) TNFA (2308 A) minor allele and IL-9 (113M) minor allele
and IL-1B (59UTR T) minor allele and VCAM-1 (21594 C) minor allele. BOTTOM, L2 is a combination of TNFA (2308 G) major allele and VDR (intron G)
minor allele, and either IL-4R (50V) minor allele or ICAM-1 (56M) minor allele: Logit P (TT=1| risk inflammatory SNPs)=0.3–1.6*L1+2.6*L2. L1=((((TNFA
(2308 A) minor allele) and (LTA (252 A) minor allele)) and ((VCAM1(21594 C) minor allele) and (SCYA 11 (A23T) minor allele))) OR (((TNFA (2308 A)
minor allele) and (IL-9 (T113M) minor allele)) and ((IL-1B (59UTR T) minor allele) and (VCAM1 (21594 C) minor allele)))). L2=(((TNFA (2308 G) major
allele) and (VDR (intron G) minor allele)) AND ((IL-4R (I50V) minor allele) or ICAM1 (K56M))).
doi:10.1371/journal.pone.0003600.g002
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to the foci of infection are a family of adhesion molecules. VCAM-
1 is a member of the IgG superfamily that is expressed on
endothelial cells and leads to the adhesion of lymphocytes via a4b1
integrins [51]. In peripheral endothelia, especially in the
conjunctiva, polymorphonuclear leukocytes act as generators of
the inflammation processes [52,53]. To our knowledge, we are the
first to report an association between TT and the VCAM1 (21594
TC) polymorphism where heterozygosity (TC) decreased the odds
of TT [O.R.=0.47 (0.25–0.86), p-value=0.015-MLR]. ICAM-1
and VCAM-1 have been found to be significantly elevated in the
vasculature after genital chlamydial infection in the murine model
[54–56]. VCAM-1 has also been associated with a Th1 immune
response and clearance of chlamydial infection [55]. Interestingly,
VCAM-1 is induced by LTA, and by the LTA (252 A) SNP [57].
Thus, variation in LTA and adhesion molecules may increase
homing of T cells to the mucosa, which might play a significant
role in clearance and prevention of disease progression to TT.
It is well-documented that cellular-mediated immunity is critical
in eliciting protection against C. trachomatis [58–60]. We were
therefore interested in studying multiple SNP polymorphisms
within the Th1/Th2/Th3 cytokine family. In our previous study,
we demonstrated that Th1 and some Th2 cytokines were
protective against chronic, scarring trachoma [14]. The IL9 gene
loci is assigned to chromosome 5q31.1, similar to other Th2
cytokines, including IL-4, IL-5 and IL-13 [61]. On the IL-9
protein, a cytosine at amino acid position 338 in exon 5 is
substituted by thymine, resulting in a non-synonymous mutation
from a hydrophilic threonine to a hydrophobic methionine at
position 113 (T113M). In our study, the IL-9 major allele
frequency (T113M) differed significantly between cases (0.96)
and controls (0.84, p=0.001, Table 2), and heterozygosity
exhibited protection against TT in our population (O.R.=0.25,
p=0.004, Table 4). IL-9 is a pleiotropic cytokine produced
primarily by Th2 lymphocytes [62]. It has been associated with
proliferation and maturation of both lymphoid and myeloid cell
progenitors [63] as well as growth factor for activated T
lymphocytes [64]. Physiologically, it causes decreased levels of
the proinflammatory cytokines TNF-a, IL-12p40, and IFN-c
while increasing the levels of anti-inflammatory IL-10 [65,66]. The
association of elevated IL-10 mRNA expression and protein levels
with TS and TT has been well documented [12–14,67], suggesting
a plausible biological role for the IL9 polymorphism in disease
pathogenesis.
Logic regression is particularly appropriate for determining
multiple interactions among many polymorphisms, and accounts
for multiple comparisons. Our results indicate the importance of
the effect of interacting gene variants on disease susceptibility. We
showed that different combinations of SNPs had a synergistic
effect on TT. The combination of TNFA (2308 G) major allele,
and VDR (intron G) minor allele, and either IL4R (I50V) minor
allele or ICAM1 (K56M) minor allele significantly increased the
odds of TT [odds ratio=13.5 (95% confidence interval 3.3–22),
p=0.001]. Individually, none of these SNPs was statistically
associated with TT. SNP interactions that are repeatedly detected
might indicate immune pathways that could be contributors to
disease pathogenesis, and could be used as markers for individuals
at risk for disease progression.
We confirmed significant associations between TNFA and LTA
polymorphisms and TT, and showed for the first time an
association between VCAM1 (21594 TC) and IL9 (T113M)
polymorphisms and protection from TT. More importantly, this
study indicates that interacting SNPs likely have a synergistic effect
on disease. Our findings lay the foundation for selecting additional
genes to study that may be in linkage disequilibrium with the SNPs
that we found to be associated with TT. In addition, it will now be
possible to determine whether dysregulated cytokine and/or
chemokine production are associated with the susceptibility
variants. These will be important next steps in trachoma research.
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